Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cosimo G Fortuna

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
European Journal of Medicinal Chemistry|October 17, 2017
Effect of mofezolac-galactose distance in conjugates targeting cyclooxygenase (COX)-1 and CNS GLUT-1 carrierMaria Grazia Perrone, Paola Vitale, Savina Ferorelli, et al.
European Journal of Medicinal Chemistry|July 16, 2017
Structural basis for selective inhibition of Cyclooxygenase-1 (COX-1) by diarylisoxazoles mofezolac and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6)Gino Cingolani, Andrea Panella, Maria Grazia Perrone, et al.
Pharmaceuticals (Basel, Switzerland)|September 27, 2025
Covalently Functionalized Halloysite-Calixarene Nanotubes for Injectable Hydrogels: A Multicavity Platform for Hydrophobic Drug DeliveryGiuseppe Cinà, Marina Massaro, Andrea Pappalardo, et al.
European Journal of Medicinal Chemistry|July 2, 2013
New linezolid-like 1,2,4-oxadiazoles active against Gram-positive multiresistant pathogensCosimo G Fortuna, Carmela Bonaccorso, Alessandra Bulbarelli, et al.
Pharmaceutics|November 27, 2024
Halloysite Nanotube-Based Delivery of Pyrazolo[3,4-<i>d</i>]pyrimidine Derivatives for Prostate and Bladder Cancer TreatmentMarina Massaro, Rebecca Ciani, Giancarlo Grossi, et al.
Bioorganic & Medicinal Chemistry|December 4, 2014
New potent antibacterials against Gram-positive multiresistant pathogens: effects of side chain modification and chirality in linezolid-like 1,2,4-oxadiazolesCosimo G Fortuna, Roberto Berardozzi, Carmela Bonaccorso, et al.
European Journal of Medicinal Chemistry|November 1, 2020
An attempt to chemically state the cross-talk between monomers of COX homodimers by double/hybrid inhibitors mofezolac-spacer-mofezolac and mofezolac-spacer-arachidonic acidMaria Grazia Perrone, Morena Miciaccia, Paola Vitale, et al.
Journal of Medicinal Chemistry|February 20, 2025
ONC201-Derived Tetrahydropyridopyrimidindiones as Powerful ClpP Protease Activators to Tackle Diffuse Midline GliomaMorena Miciaccia, Olga Maria Baldelli, Cosimo G Fortuna, et al.
European Journal of Medicinal Chemistry|December 28, 2018
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viabilityMaria Laura Pati, Paola Vitale, Savina Ferorelli, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
European Journal of Medicinal Chemistry|October 17, 2017
Effect of mofezolac-galactose distance in conjugates targeting cyclooxygenase (COX)-1 and CNS GLUT-1 carrierMaria Grazia Perrone, Paola Vitale, Savina Ferorelli, et al.
European Journal of Medicinal Chemistry|July 16, 2017
Structural basis for selective inhibition of Cyclooxygenase-1 (COX-1) by diarylisoxazoles mofezolac and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6)Gino Cingolani, Andrea Panella, Maria Grazia Perrone, et al.
Pharmaceuticals (Basel, Switzerland)|September 27, 2025
Covalently Functionalized Halloysite-Calixarene Nanotubes for Injectable Hydrogels: A Multicavity Platform for Hydrophobic Drug DeliveryGiuseppe Cinà, Marina Massaro, Andrea Pappalardo, et al.
European Journal of Medicinal Chemistry|July 2, 2013
New linezolid-like 1,2,4-oxadiazoles active against Gram-positive multiresistant pathogensCosimo G Fortuna, Carmela Bonaccorso, Alessandra Bulbarelli, et al.
Pharmaceutics|November 27, 2024
Halloysite Nanotube-Based Delivery of Pyrazolo[3,4-<i>d</i>]pyrimidine Derivatives for Prostate and Bladder Cancer TreatmentMarina Massaro, Rebecca Ciani, Giancarlo Grossi, et al.
Bioorganic & Medicinal Chemistry|December 4, 2014
New potent antibacterials against Gram-positive multiresistant pathogens: effects of side chain modification and chirality in linezolid-like 1,2,4-oxadiazolesCosimo G Fortuna, Roberto Berardozzi, Carmela Bonaccorso, et al.
European Journal of Medicinal Chemistry|November 1, 2020
An attempt to chemically state the cross-talk between monomers of COX homodimers by double/hybrid inhibitors mofezolac-spacer-mofezolac and mofezolac-spacer-arachidonic acidMaria Grazia Perrone, Morena Miciaccia, Paola Vitale, et al.
Journal of Medicinal Chemistry|February 20, 2025
ONC201-Derived Tetrahydropyridopyrimidindiones as Powerful ClpP Protease Activators to Tackle Diffuse Midline GliomaMorena Miciaccia, Olga Maria Baldelli, Cosimo G Fortuna, et al.
European Journal of Medicinal Chemistry|December 28, 2018
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viabilityMaria Laura Pati, Paola Vitale, Savina Ferorelli, et al.
Pageof 4